Background Adherence to treatment is an indicator of treatment success. Long‐term data on
adherence to biologic treatment in psoriasis are lacking. Objectives To compare the tumour …

Letters to the Editor blockers, have also been approved in Taiwan for psoriasis patients who
failed previous phototherapy and pervious systemic therapy. Ustekinumab is a novel …

Background There are limited long‐term,'real‐world'data on ustekinumab, or the effect of
dose adjustment in suboptimal responders. Objectives We describe 52‐week data from …

Drug survival studies have been utilized to evaluate the real-world effectiveness of biologics
used in psoriasis. However, the increasing volume of drug survival data suffers from large …

Background: The use of biologic medications for psoriasis is a recent therapeutic advance.
Objective: To review clinical and economic data for biologic therapies in the treatment of …

Dermatologists may choose from various conventional and biological systemic agents to
treat patients with moderate‐to‐severe psoriasis. We set out to analyse systematically the …

To the Editor: A 53-year-old Russian man was under our care for severe long-standing
psoriasis (37 years) and psoriatic arthritis mutilans (17 years) of the hands requiring …

Introduction Theoretical risks of biologic agents remain under study. Objective The aim of
this study was to integrate 1-year safety data from 12 ustekinumab registrational trials …

Background Adherence is an overall marker of treatment success, and it depends on
multiple factors including efficacy and safety. Despite the wide use of tumour necrosis factor …

Ustekinumab, a human anti‐interleukin (IL)‐12/IL‐23p40 monoclonal antibody has
demonstrated significant efficacy in patients with moderate‐to‐severe psoriasis. Skin lesion …